Morningstar® Stock Report™

Novartis AG NOVN

Letzte Unternehmensnews

DatumZeitQuelleTitelTyp
Previous Stories...
24.05.201916:41NASDAQNEWSAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and FamiliesADH
24.05.201916:32NASDAQNEWSAveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)ADH
08.05.201922:20NASDAQNEWSNovartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye careADH
24.04.201905:00NASDAQNEWSNovartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgradedQRF
26.03.201923:35NASDAQNEWSNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active diseaseADH
26.03.201923:35HUGINNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active diseaseADH
22.03.201906:00HUGINNovartis plans for Alcon spin-off on April 9, 2019ADH
25.02.201922:55HUGINNovartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-offTAB
30.01.201915:17HUGINNOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018ACS
30.01.201906:00HUGINNovartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018ADH
21.12.201813:53HUGINNovartis successfully completes acquisition of EndocyteADH
20.12.201806:00HUGINNovartis announces new CEO of Oncology Business UnitADH
13.11.201821:29HUGINAlcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and LondonADH
18.10.201805:00HUGINNovartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growthQRT
23.08.201805:15HUGINSOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutationRES
27.07.201812:53HUGINSandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)ADH
18.07.201805:00HUGINNovartis delivers solid growth in second quarter and continues transformation to a focused medicines companyADH
29.06.201812:10HUGINNovartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in EuropeADH
29.06.201805:00HUGINNovartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bnADH
01.06.201812:00HUGINNovartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billionADH